Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.
Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.
Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.
Dr. Harwin de Vries is an Associate Professor at the Department of Technology and Operations Management, Rotterdam School of Management (RSM), Erasmus University Rotterdam. His research focuses on health and humanitarian logistics, particularly disaster relief logistics and improving access to essential medicines in low- and middle-income countries (LMICs). He explores the role of data analytics and new operational models in healthcare systems, such as mobile health service delivery. Before joining RSM, he worked at INSEAD as a postdoctoral researcher and manager of the INSEAD Humanitarian Research Group. He holds a PhD in Operations Research from Erasmus University. Education: PhD in Operations Research, Erasmus University Rotterdam His research interests include optimizing supply chain decisions in humanitarian contexts, with over 20 collaborations with health organizations. He teaches courses on Health & Humanitarian Logistics, Business Analytics, and Spreadsheet Modelling across BSc, MSc, and EMBA programs. Dr. de Vries has received notable awards including the 2021 ERIM Award for Young Researcher and a 2022 NWO VENI Grant. His work has been published in leading journals like Production and Operations Management and Manufacturing & Service Operations Management, and has been transformed into teaching cases. Grants: NWO VENI Grant (2022) He serves on the board of the POMS College of Humanitarian Operations & Crisis Management, actively contributing to academic and practical solutions in humanitarian logistics.
Brooke Hudspeth, PharmD, is an Associate Professor and Chief Practice Officer at the University of Kentucky (UK) College of Pharmacy. She oversees community pharmacy initiatives and serves as acting President of the Kentucky Pharmacists Association (KPhA). Her roles include mentoring pharmacy students and residents as a preceptor, and leading collaborative projects with organizations like the American Pharmacists Association Foundation, Kroger Co., and the CDC. Educationally, she holds a Doctor of Pharmacy from the UK College of Pharmacy, alongside PGY1/PGY2 Community-based Pharmacy Practice Residencies from the same institution. Her research focuses on diabetes prevention, obesity, and pharmacist-driven clinical services, particularly through expanding the National Diabetes Prevention Program (NDPP) to five U.S. states via a $7.5M CDC grant. Research interests emphasize health disparities, vaccine accessibility, and optimizing pharmacist roles in self-care conditions. Notable projects include influenza point-of-care testing and pharmacy partnerships during the pandemic. Her work bridges academic innovation with real-world healthcare challenges, advocating for policy changes to enhance pharmacist payment for clinical services. Despite no explicitly listed awards, her impactful grant-funded projects reflect significant contributions to public health. She advises students and residents while leading residency expansion initiatives. Collaborations with major institutions underscore her role in advancing pharmacy practice and education nationally. Hudspeth’s lab/team is embedded within UK’s College of Pharmacy, focusing on translational research to improve patient care through pharmacist-led interventions. Future work includes expanding telehealth pharmacy services and addressing healthcare workforce shortages.
Francesco Pilati is an Associate Professor at the Department of Industrial Engineering, University of Trento, where he serves as local coordinator for the scientific field ING-IND/17 (Industrial Plants and Logistic Systems). He chairs the research group on Industrial Plants, Production Systems, and Logistics, and teaches courses in Industrial Plants and Design of Digital Production and Assembly Systems. As coordinator of the Master's program in Management and Industrial Systems Engineering and University Coordinator for the EIT double degree in Zero-Defect Manufacture, Pilati bridges academic leadership with advanced manufacturing research. He has also served as Invited Lecturer at universities in Vienna and Göttingen. His research focuses on integrating environmental sustainability with technical-economic criteria through multi-objective optimization and impact assessment. Key areas include: Distribution networks and warehousing systems Manufacturing and assembly line design Hybrid energy production systems Digitization of manual production processes using depth cameras Recent publications highlight applications of Industry 4.0 technologies to pandemic safety, logistics optimization, and smart manufacturing. Pilati has received significant recognition including the Philip Morris Italia Empowering Research Award (2016) and Autostrade per l'Italia academic recognition. His editorial contributions include guest editing special issues on Digital Twins and Smart Factories in Q1 journals.
Ashli Owen-Smith is a behavioral scientist affiliated with the School of Public Health at Georgia State University , where her research focuses on mental health disparities, suicide prevention, and integrative/complementary approaches for complex mental-physical health conditions. She works with underserved populations including refugees/immigrants, incarcerated individuals, and LGBTQ+ communities through community-based participatory research and mixed-methods frameworks. Her current projects are funded by CDC , DBHDD , and DPH . Education: Ph.D. in Behavioral Sciences (Emory, 2009), S.M. in Public Health (Harvard, 2005), B.A. in Psychology (Smith College, 2001) Her research spans mental health , trauma , suicide prevention , and mindfulness-based interventions . Recent work examines telehealth adaptations for chronic pain and mental health, vaccine hesitancy in refugee communities, and social determinants of suicide . She leads studies on gender-affirming care and health disparities in LGBTQ+ populations. Key article trends include epidemiological analysis of suicide risk factors, COVID-19 impacts on mental health, ICD-10 coding for autism, and complementary medicine in trauma recovery. Subfields span telehealth , health equity , mental-physical comorbidity , and community engagement . Students she has mentored include C.A. Scarlett , T. Griner , and M.M. Sesay . Her work integrates public health policy , clinical research , and health systems analysis .
Pinar Keskinocak serves as the H. Milton and Carolyn J. Stewart School Chair and Professor in the H. Milton Stewart School of Industrial and Systems Engineering at the Georgia Institute of Technology. She co-founded and directs the Center for Health and Humanitarian Systems, demonstrating leadership in both academic administration and research innovation. Her career includes prior roles as College of Engineering ADVANCE Professor and interim associate dean for faculty development, alongside industry experience at IBM T.J. Watson Research Center. Her educational foundation includes a Ph.D. in Operations Research from Carnegie Mellon University and M.S. and B.S. degrees in Industrial Engineering from Bilkent University. This rigorous training underpins her interdisciplinary approach to complex societal challenges. Dr. Keskinocak's research pioneers operations research applications for societal impact , with dual emphases on health systems and humanitarian logistics . She develops advanced models for infectious disease dynamics (including COVID-19, malaria, and Guinea worm), vaccination strategies, disaster response, and supply chain optimization. Her work uniquely bridges engineering analytics with real-world implementation through partnerships with the CDC, American Red Cross, Carter Center, and Children's Healthcare of Atlanta. Analysis of her 2023-2025 publications reveals intensifying focus on eradication program modeling for polio and Guinea worm, with increasing integration of machine learning for predictive accuracy in vaccine distribution. A pronounced trend addresses health equity through targeted interventions for under-immunized populations in Sub-Saharan Africa, emphasizing resource allocation under constraints and cross-border coordination challenges. Her scientific recognition includes: INFORMS Fellow (2015) NSF CAREER Award (2001) Outstanding Professional Education Award, Georgia Tech (2018) Denning Award for Global Engagement, Georgia Tech (2016) Women in Engineering Excellence Teaching Award (2005) Moving Spirit Award, INFORMS (2005) Dr. Keskinocak has secured extensive project funding through collaborations with federal agencies and NGOs, directing research on pandemic response systems, vaccine logistics, and disaster debris management. While specific advisees aren't publicly cataloged, her leadership in the Center for Health and Humanitarian Systems mentors numerous graduate researchers through interdisciplinary projects. She significantly influences national policy via National Academies committees addressing supply chain resilience and vaccine distribution infrastructure. The Center for Health and Humanitarian Systems operates as a dynamic hub where engineering rigor meets humanitarian action, coordinating multi-institutional teams to develop deployable solutions for global health crises and disaster response systems.
William John Moss is a Professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health, where he also holds joint appointments in International Health and Molecular Microbiology and Immunology. He serves as Executive Director of the International Vaccine Access Center (IVAC) and Deputy Director at the Johns Hopkins Malaria Research Institute. His work spans multiple centers including the Center for Global Health, Center for Humanitarian Health, and Johns Hopkins Vaccine Initiative. Dr. Moss earned his MD from Columbia University in 1984 and his MPH in 1995. As a pediatrician with subspecialty training in infectious diseases, he has conducted extensive field research across multiple countries including Ethiopia, Kenya, South Africa, Zambia, Zimbabwe and India. His research focuses on the epidemiology and control of childhood infections in resource-poor settings, with particular emphasis on measles-HIV interactions, malaria transmission in southern Africa, serosurveillance for immunization programs, and care of HIV-infected children in rural Zambia. His recent work (2024-2025) demonstrates continued focus on measles epidemiology, malaria transmission dynamics, and vaccine implementation research, with numerous publications examining immunity gaps, human mobility patterns, and malaria vector biology in African settings. Scientific Awards: Wyeth-Lederle Vaccines and Pediatrics Young Investigator Award in Vaccine Development (1999-2001) Gustave J. Martin Innovative Research Fund Fellow (2001) Advising, Mentoring and Teaching Recognition Award (2007-2008) Dr. Moss leads multiple research projects including studies on HIV-infected children's immune reconstitution, malaria transmission dynamics in southern Zambia, and strengthening immunization systems through serosurveillance. His work bridges clinical medicine, epidemiology, and public health policy to address critical challenges in global infectious disease control.
Melanie Molina, MD, MAS is an Assistant Professor of Emergency Medicine at the University of California, San Francisco (UCSF) and Affiliate Faculty of the Philip R. Lee Institute for Health Policy Studies. She serves as Co-Director of the Social Emergency Medicine and Health Equity Section and holds a secondary appointment in the Department of Medicine’s Division of Clinical Informatics and Digital Transformation. Clinically, she works at Zuckerberg San Francisco General Hospital and UCSF Medical Center. National Clinician Scholars Program Fellowship (2023) MAS in Clinical Research, UCSF (2023) Residency in Emergency Medicine, Harvard Medical School (2021) MD in Medicine, The University of Texas at Austin (2017) BS/BA in Biology and Hispanic Studies, The University of Texas at Austin (2012) Dr. Molina’s research centers on leveraging technology to address social determinants of health in emergency settings, with a focus on vulnerable populations. Her work spans health equity, opioid use disorder interventions, microaggressions in healthcare, and clinical informatics. She pioneers EHR-enabled tools to integrate social care into emergency clinical workflows while minimizing clinician burden. Her NIH-funded projects emphasize practical solutions for racial and ethnic health disparities, particularly in vaccine delivery and social risk documentation. Her recent publications (2024-2025) reveal three dominant trends: (1) Integration of AI and informatics for social risk screening and clinical decision support, (2) Health equity interventions targeting vaccine hesitancy and long COVID disparities, and (3) Critical analysis of DEI implementation challenges in academic emergency medicine. The work consistently bridges technical innovation with community-centered approaches to address systemic inequities. National Institutes of Health NIDA Loan Repayment Award (2024-2025) National Hispanic Medical Association Top 40 Under 40 (2024) UCSF John A. Watson Faculty Scholar (2023) National Institutes of Health NIAID Loan Repayment Award (2022-2024) Academy for Women in Academic Emergency Medicine Outstanding Research Publication Award (2021) Harvard Medical School Presidential Scholars Public Service Initiative Award (2017) Dr. Molina actively mentors medical students, residents, and fellows in health equity research. As Principal Investigator on multiple NIH and foundation grants—including the Harold Amos Medical Faculty Development Program grant ($825,575, 2024-2028) and an NIH/NIDA K23 award (2024-2029)—she leads projects developing EHR-integrated interventions for social risk documentation and opioid use disorder treatment. Her PROBOOSTVAXED trial addresses vaccine hesitancy through ED-based delivery across eight U.S. cities. She co-directs the Social Emergency Medicine and Health Equity Section within UCSF’s Department of Emergency Medicine, collaborating closely with the Action Research Center for Health Equity and the Philip R. Lee Institute for Health Policy Studies. Her team integrates clinical informatics expertise with community health workers to develop scalable solutions for social risk mitigation in safety-net emergency departments.
Dr. Channakeshava S. Umeshappa is a faculty member in the Department of Microbiology & Immunology and Department of Pediatrics at Dalhousie University, Canada . He holds a PhD in Immunology from the University of Saskatchewan and completed postdoctoral training at the University of Calgary. Education : DVM (Karnataka Veterinary Animal and Fisheries Sciences University, India), MVSc (Indian Veterinary Research Institute, India), PhD (University of Saskatchewan, Canada) Research Interests : Dr. Umeshappa’s program focuses on immunoregulation in chronic diseases , particularly autoimmunity and cancer. His lab employs genetically modified murine models , omics , synthetic biology , flow cytometry , and imaging to develop immunotherapies. His work emphasizes interdisciplinary collaboration with clinicians and scientists. Article Trends : Recent publications highlight nanomedicine applications in autoimmune liver disease (e.g., peptide-MHC nanomedicines, invariant NKT cell reprogramming) and cancer therapy (e.g., laser-responsive nanoparticles, tumor-to-lymph gels). Studies span immuno-informatics , cell signaling , and clinical outcomes analysis.
Theresa Raimondo is the Manning Assistant Professor of Engineering at Brown University, with a secondary appointment in the Division of Biology and Medicine. She joined the Brown Engineering faculty in January 2024 after completing her postdoctoral training at MIT's Koch Institute. Dr. Raimondo leads the Raimondo Research Lab, which focuses on chemically modifying RNA and designing nanoparticles for therapeutic delivery to the body, an immunotherapy concept that holds immense promise in the field of immunoengineering. Her educational background includes: PhD in Engineering Sciences – Bioengineering from Harvard University (2019) MEng from Harvard University (2019) Sc.B. in Chemical and Biochemical Engineering from Brown University (2011) Dr. Raimondo's research is broadly focused on the design of targeted drug-delivery vectors and novel RNA-based therapeutics for applications in cancer, immunotherapy, and tissue regeneration. Her work primarily centers on developing novel lipid nanoparticles (LNPs) for RNA-based therapies, contributing to adjuvanted mRNA-based vaccines and siRNA-based cancer immunotherapies. By optimizing LNP formulation and modulating RNA constructs, she seeks to understand how RNA-LNPs modulate immunity and develop new therapeutic approaches. Her expertise spans biomaterials, drug delivery, biomolecular engineering, nanomedicine, tissue engineering, and regenerative medicine. Analysis of Dr. Raimondo's recent publications reveals a strong focus on RNA delivery systems and lipid nanoparticle technology. Her work spans from fundamental studies on nanoparticle design to applications in cancer immunotherapy, vaccine development, and tissue regeneration. A significant portion of her research involves optimizing lipid formulations for improved mRNA delivery and exploring how these systems interact with the immune system. Her publications demonstrate a trajectory from basic biomaterials research to increasingly translational work with therapeutic applications. Dr. Raimondo has received numerous prestigious awards: 2025 NAE Symposium selection (Grainger Foundation Frontiers of Engineering) 2025 appointment to the inaugural Early Career Board of ACS Applied Bio Materials 2024 selection as MIT Faculty Founder Initiative finalist 2022 Convergence Scholar fellowship from MIT's Marble Center for Cancer Nanomedicine National Science Foundation graduate research fellowship Harvard's Smith family graduate fellowship Dr. Raimondo is actively involved in mentoring students through courses including ENGN 0931L - Biomedical Engineering Design and Innovation II, ENGN 1490 - Biomaterials, and ENGN 1931L - Biomedical Engineering Design and Innovation II. Her research program is supported by various grants, though specific funding sources aren't detailed in the provided text. The Raimondo Research Lab represents a dynamic environment where engineering principles are applied to solve complex biological challenges in drug delivery and regenerative medicine. The Raimondo Research Lab at Brown University serves as a hub for innovation in RNA delivery and biomaterials design. The lab brings together expertise in chemical engineering, molecular biology, and immunology to develop next-generation therapeutic platforms. Current research directions include optimizing lipid nanoparticle formulations, exploring novel RNA modifications, and investigating immune responses to RNA therapeutics across various disease contexts.
Dr. Vikas Srivastava is an Associate Professor of Engineering and Director of the Graduate Program in Biomedical Engineering at Brown University's School of Engineering. His research focuses on solid mechanics, continuum biomechanics, and cell mechanics, with applications in materials under extreme environments and biomedical science. He leads the Srivastava Lab for Solid Mechanics and Biomechanics, which integrates computational models with experimental techniques to address interdisciplinary challenges. Dr. Srivastava holds a Ph.D. in Mechanical Engineering from MIT (2010) and previously held senior roles at ExxonMobil, including leadership in materials mechanics and deepwater drilling engineering. His academic career at Brown began in 2018, during which he has directed over 15 graduate students and secured notable funding. His research interests span mechanobiology, hydrogel-based drug delivery systems, AI-driven predictive modeling, and biomaterial innovations for cancer therapies. He has pioneered physics-informed neural networks for material characterization and developed novel hydrogels to enhance chemotherapy efficacy. Recent articles highlight advancements in polymer fracture modeling, machine learning for non-destructive evaluation, and predictive epidemiological modeling for pandemics. Dr. Srivastava has received the Dean’s Award in Bioengineering and was promoted to tenured Associate Professor in 2023. He actively mentors students through grants like the NSF Graduate Research Fellowship and leads initiatives in biomedical technology translation. The Srivastava Lab collaborates extensively across engineering, biology, and medicine to advance translational research in materials science and clinical applications.
Dr. Margaret Elizabeth Kruk is a Professor of Health Systems at the Harvard T.H. Chan School of Public Health, part of Harvard University. She previously held roles as Associate Professor at Columbia University and Assistant Professor at the University of Michigan. Her research focuses on improving health system quality in low-income countries, using implementation science and econometric methods to evaluate large-scale reforms. She chairs the Lancet Global Health Commission on High Quality Health Systems in the SDG Era and directs the QuEST Network, a multi-country initiative to enhance health systems globally. Education: MD from McMaster University, MPH from Harvard University. Affiliations: Director of QuEST Centers and Network, former roles at UNDP and McKinsey & Company. Her research interests span healthcare quality measurement, maternal and newborn health, and policy solutions for systemic deficits. Key projects include the People’s Voice Survey on health system performance and mobile phone eCohorts for tracking care quality in LMICs. Publications highlight maternal health outcomes, vaccination decision-making, and health system confidence across countries. Grants include NIH funding for maternal-newborn health integration with HIV programs in Tanzania. Twitter: @mkruk
Naomi Rogers, Ph.D. (She/Her) is Professor of the History of Medicine in the Section of the History of Medicine and the Program in the History of Science and Medicine at Yale University. She holds courtesy appointments in the History Department and the Women's, Gender and Sexuality Studies Program, and serves on Yale's Dean's Advisory Council for LGBTQI Affairs. Professor Rogers teaches undergraduate, graduate, and medical students, regularly lecturing on the history of AIDS, reproduction, health economics, eugenics, nutrition, disability, and health activism. Professor Rogers' educational background includes: PhD in History from University of Pennsylvania (1986) MA from University of Pennsylvania (1986) BA in Music from Melbourne University (1980) BA with Honors from Melbourne University (1979) Her research focuses on 20th and 21st century history of medicine with emphasis on health inequities and social justice. Professor Rogers' historical interests span gender and health, disease and public health, disability studies, feminism, alternative medicine, health policy, and health activism. Her work critically examines the intersection of medical practices with social movements, particularly how marginalized communities have challenged medical orthodoxy throughout American history. She has published extensively in journals such as American Journal of Public Health, Bulletin of the History of Medicine, Journal of Medical Humanities, Radical History Review, Social History of Medicine, and Women and Health. Professor Rogers' recent scholarship demonstrates a consistent focus on the historical dimensions of contemporary health issues, particularly vaccine politics, abortion history, and community health activism. Her publications reveal patterns of resistance to medical authority, the role of race and gender in shaping health outcomes, and the historical roots of current health justice movements. Her work bridges academic history with public engagement, as evidenced by her frequent media commentary on COVID-19 and other health issues in outlets including BBC Radio, CNN, Huffington Post, National Public Radio, New York Times, Wall Street Journal, and Washington Post. Among her notable recognitions: AAHN's Lavinia L. Dock Award for Exemplary Historical Research for 'Polio Wars: Sister Kenny and the Golden Age of American Medicine' (2014) Presenter of the AAHM's Garrison Lecture: 'Radical Visions of American Medicine: Politics and Activism in the History of Medicine' (2017) Professor Rogers has been actively involved in academic leadership and mentoring. She has served as Director of Graduate Studies for the 2022-23 academic year, Chair of the Women's Faculty Forum, and Liaison to the Committee on Status of Women in Medicine. Her service extends to editorial boards including the Journal of the History of Medicine and Allied Sciences since 2018. She has also contributed to public understanding of medicine through consultations for documentaries including 'The Polio Crusade' (PBS), 'On the Basis of Sex' (Focus Features), and 'War on Science' (in process). Currently, Professor Rogers serves on the Medical School's OBGYN 'Dobbs' Sessions Planning Committee, which has organized webinars for the Yale community, and was co-organizer of the history-themed session 'Rooted in History: Abortion, Law and American Health Care.' She is working on her book project 'Health Radicalism and the Humanization of American Medicine' (under contract with Oxford), examining critics of medical orthodoxy since 1945 including civil rights, consumer, and feminist activists. She also conducts ongoing research on antisemitism in American medicine in the decades before and after World War II.
